An Open-Label Study in Pediatric (<18 Years of Age), Severe Hemophilia A Participants (Coagulation Factor Activity <1%) With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With or Without Inhibitors Comparing 12 Months of Historical Standard Treatment to Marstacimab Prophylaxis